Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy?

Key Points

• Anbio Biotechnology shares gapped up — the stock moved from a prior close of $21.51 to an open of $22.79 and last traded at $23.06 on light volume (564 shares).
• Weiss Ratings upgraded the stock from "sell (d+)" to "hold (c-)," and MarketBeat lists the company's average analyst rating as "Hold."
• In the most recent quarter Anbio reported EPS of $0.04 and revenue of $2.29 million.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $21.51, but opened at $22.79. Anbio Biotechnology shares last traded at $23.06, with a volume of 564 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, February 9th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold".

Anbio Biotechnology Stock Performance

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last posted its earnings results on Tuesday, December 30th. The company reported $0.04 EPS for the quarter. The company had revenue of $2.29 million for the quarter.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.